TG4010

BACKGROUND MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a… (More)

TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as… (More)

Several immunotherapy drugs are today tested in this disease in advanced stages of development. TG4010 (Transgene SA) is one of… (More)

BACKGROUND Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted… (More)

MUC1 over-expression in renal clear-cell carcinoma (RCC) is associated with poor prognosis. This phase II study determined the… (More)

3027 Background: TG4010 is a targeted immunotherapy product. It was tested in combination with first-line chemotherapy in a… (More)

BACKGROUND TG4010 is a recombinant viral vector expressing both the tumor-associated antigen MUC1 and Interleukine-2. This vector… (More)

Purpose: TG4010 is a recombinant MVA vector expressing the tumor-associated antigen MUC1 and IL2. We explored the effect two… (More)

Vaccines are well known in the context of prevention of diseases caused by infectious agents. Current research is now aimed at… (More)

BACKGROUND The MUC1 protein is a highly glycosylated mucin normally found at the apical surface of mucin-secreting epithelial… (More)